Donate

industry_news_banner

Note: The followed is excerpted from a press release from uniQure.聽Read uniQure’s full press release HERE.聽


uniQure announced today聽plans to advance their development program for hemophilia B gene therapy into a pivotal study using an enhanced version of their聽product candidate called AMT-061. AMT-061 is identical to AMT-060 in every way apart from a change from the wild-type Factor IX gene to what is commonly known as the 鈥淧adua鈥 gene 鈥 a variant of the Factor IX gene that has been shown to provide substantial increases in Factor IX activity compared to the wild-type gene used in AMT-060.

 


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.